Complementary and adjunctive therapies are increasingly being explored to enhance asthma control and reduce airway inflammation. Nigella sativa (black seed) is a medicinal plant used traditionally in multiple regions and has demonstrated anti-inflammatory, immunomodulatory, and bronchodilator effects. Its potential as an adjuvant therapy in asthma has attracted attention in both preclinical and clinical research
Children aged 6-18 years
Diagnosed with moderate persistent asthma according to the Global Initiative for Asthma (GINA) 2022 guidelines
Receiving stable standard controller therapy (inhaled corticosteroids ± long-acting β2-agonists) for at least 4 weeks prior to enrollment
Able to perform reproducible spirometry
History of severe asthma exacerbation requiring ICU admission in the past 3 months
Use of systemic corticosteroids within 4 weeks prior to enrollment
Known hypersensitivity to Nigella sativa or its components
Other chronic respiratory diseases (e.g., cystic fibrosis, bronchiectasis)